Research has identified the siglec-15/sialic acid axis as a key glyco-immune checkpoint in breast cancer bone metastasis. This discovery may have implications for understanding and potentially treating bone tumors, with studies exploring the role of glyco-immune checkpoints in various types of cancer. The findings suggest a potential new pathway for treating breast cancer bone metastases, although the specifics of the treatment approach are not yet clear.